Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca Investors Nervous as Recovery Hinges on Success of New Meds, Key Drug Data

AstraZeneca said profit and revenue streams will likely fall in 2017 as generic drugs eat into the market share of its blockbuster anti-cholesterol drug Crestor.

Read More »

U.S. court ruling on MS drug deals blow to Teva

A bitter defeat in a U.S. patents case is the latest in a series of setbacks for Teva that has investors calling for major changes at the generic drugmaker.

Read More »

Lilly CEO Shakes Up Leadership Structure

Eli Lilly is looking to begin 2017 with a series of organizational changes that includes changes in some leadership roles.

Read More »

Allergan to buy Acelity’s tissue unit LifeCell

Drugmaker Allergan Plc said it would buy LifeCell – a regenerative medicine unit owned by privately held Acelity LP Inc. – for $2.9 billion in cash.

Read More »

Mylan to pay $465 million over EpiPen Medicaid rebate dispute

Mylan NV will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment.

Read More »

Pfizer abandons plan to split into two companies

Pfizer, which was considering a split into two companies for more than two years, said it would not do so because the move would not create any shareholder value.

Read More »

Endo CEO steps down; successor named

Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli.

Read More »

Novo Nordisk cuts forecasts on tough U.S. market

Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.

Read More »

Bristol-Myers shares hit by decline of Yervoy

Bristol-Myers Squibb reported disappointing 2Q 2016 sales of its Yervoy melanoma treatment.

Read More »

Sales of Revlimid drive Celgene profit

Celgene Corp. exceeded expectations for second-quarter 2016 earnings on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom